US$ 26.27
sanofi glp 1 GLP-1 medications have become one of the most talked-about topics in obesity medicine, but they're also surrounded by misinformation. In this carousel, I'm breaking down seven of the most common myths I caryophyllene) Arrival of GLP-1 weight-loss pill
Description
Retatrutide: Surgery-Level Results from a Triple Agonist The most striking data to emerge from the GLP-1 drug pipeline in 2026 comes from retatrutide, Eli Lillys investigational first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously

Liver Health (SYNERGY-NASH) Loomba R, Hartman ML, Lawitz EJ, et al

It does not carry the cancer risk concerns associated with elevated growth hormone

policy efforts like international benchmarking threaten to constrain it
